Stroke or cerebrovascular accident research

Stroke or cerebrovascular accident occurs due to a cerebral circulation disorder. It may be due to the obstruction of a blood vessel in the brain (clot or thrombus) or to its rupture (stroke or hemorrhage). Thus, depending on the origin of the disease, stroke can be ischemic (cerebral infarction) or hemorrhagic (cerebral hemorrhage).

The risk of stroke is increased by high blood pressure, heart disease, advanced age, diabetes, high cholesterol, atherosclerosis (accumulation of fatty deposits in the arteries) and family history of this disease. 

Stroke can cause dizziness, severe headache, numbness, weakness on one side of the body and problems speaking, writing or understanding language.

Stroke is one of the most important causes of permanent adult disability. It is the leading cause of death in women and the second leading cause in men. It is a major health problem that causes high health care costs.

Need more information?

If you are interested in learning more about our research, please contact us.

We dream of improving stroke prevention and treatment

In recent years, progress has been made in the development of diagnostic tools, but precision medicine strategies in the cardiovascular field are still lacking.


We deepen our knowledge of the molecular mechanisms that condition the occurrence of thrombotic events and resistance to treatment.


We seek to establish new biomarkers that reflect the poor vascular response and identify new therapeutic targets to prevent the development of atherosclerosis and treat the thrombotic event.


We work closely with researchers and clinicians to rapidly translate laboratory findings to the patient to improve diagnosis, treatment and prognosis.

REFERENCES IN TRANSLATIONAL RESEARCH

Atherothrombosis Research Group

Reference team in preclinical research on the most relevant inflammatory, proteolytic and prothrombotic mechanisms that lead to the progression of atherosclerosis and thrombus formation with the aim of identifying new therapies and therapeutic targets to optimize diagnosis, develop new treatments and improve the prognosis of patients with atherothrombotic cardiovascular disease.

It is part of the Cardiovascular Disease Program.